- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Human pan-cancer analysis of the predictive biomarker for the CDKN3 ; volume:29 ; number:1 ; day:8 ; month:5 ; year:2024 ; pages:1-13 ; date:12.2024
European journal of medical research ; 29, Heft 1 (8.5.2024), 1-13, 12.2024
- Creator
-
Chen, Yingjun
Li, Dai
Sha, Kaihui
Zhang, Xuezhong
Liu, Tonggang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40001-024-01869-6
- URN
-
urn:nbn:de:101:1-2407172126337.287401677886
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Yingjun
- Li, Dai
- Sha, Kaihui
- Zhang, Xuezhong
- Liu, Tonggang
- SpringerLink (Online service)
Other Objects (12)
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
NEK2 is a potential pan-cancer biomarker and immunotherapy target
Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker
Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
MCM10, a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
SLMO2 is a potential prognostic and immunological biomarker in human pan-cancer
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
NEK2 is a potential pan-cancer biomarker and immunotherapy target
Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker
Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
MCM10, a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
SLMO2 is a potential prognostic and immunological biomarker in human pan-cancer
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
NEK2 is a potential pan-cancer biomarker and immunotherapy target
Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker
Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
MCM10, a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy